How to Determine Product Classification for Overseas Registration of Home Medical Devices?

How to Determine Product Classification for Overseas Registration of Home Medical Devices?

Published: July 30, 2026, 15:48 | Updated: July 30, 2026, 15:48

Executive Summary

Determining the product classification is a critical step that defines the registration pathway, technical documentation requirements, and time to market for home medical devices in overseas markets. Enterprises should first verify whether the product falls within the scope of the target country's medical device regulations, such as whether the U.S. FDA classifies it as a medical device, the EU MDR definition, or the device recognition under GHWP member states (e.g., China, Japan, South Korea, Southeast Asia). Next, the risk class should be determined according to the target country's regulatory framework: the FDA uses Class I/II/III, the EU MDR uses Class I/IIa/IIb/III, and other GHWP members typically reference GHTF classification rules or local guidelines. Enterprises need to prepare evidence on intended use, mechanism of action, environment (home/professional), duration of body contact, and degree of invasiveness. Common risks include mistakenly treating home-use devices as "non-medical devices" leading to registration failure, or over/underestimating risk class causing unnecessary clinical trials or review delays. Enterprises should systematically collect existing documentation such as NMPA, CE, FDA, ISO 13485/MDSAP, assess reusable components, and plan ahead for local agents and labeling/localization. Post-market obligations (e.g., change notifications, adverse event reporting) must also be included in classification decisions, as maintenance costs vary significantly by risk class.

Applicable Scenarios and Core Questions

For enterprises planning to export home medical devices (e.g., blood pressure monitors, glucose meters, home ventilators, rehabilitation physiotherapy equipment) to overseas markets, product classification is the starting point of the registration process. Each country or region has different definitions and classification rules for "medical devices," which directly affect the registration pathway, technical file requirements, quality management system audits, and post-market surveillance obligations. Companies often confuse classification boundaries, such as misclassifying a Class IIb device that requires clinical data as Class I, leading to prolonged review cycles or rejection.

Core questions include: How do you determine whether the product is considered a medical device in the target country? How do you choose the appropriate risk class based on intended use, environment, and risk characteristics? Can existing CE, FDA, or NMPA classifications be directly transferred? Companies need a reusable decision logic to reduce duplication in multi-country registrations.

Classification Decision Logic

Step 1: Determine if the product falls under the target country's medical device definition. For example, the U.S. FDA defines a device in 21 CFR 801.3 as an instrument intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body, and which does not achieve its primary intended purpose through chemical action or metabolism. The EU MDR Article 2 has a similar definition but explicitly includes certain devices such as hollow fiber membranes. GHWP member states generally adopt GHTF/NBOG guidance, emphasizing "medical purpose" and "non-pharmacological action." If the product is not a medical device, it may be regulated as a general consumer product or drug, with a completely different pathway.

Step 2: Determine the risk class. For the EU MDR, classification rules (Rules 1–22) consider the site of use (e.g., central circulatory/system is Class III/IV), contact duration (≤60 minutes, ≤30 days, >30 days), degree of invasiveness (non-invasive, percutaneous, implantable), and mode of action (active therapeutic, diagnostic). Home environment may lower the class, but note that home ventilators and infusion pumps may still be classified as Class IIb. The U.S. FDA uses the classification panels under 21 CFR 862–892; most home devices are Class II, with a few as Class I (e.g., manual sphygmomanometer). Other GHWP members like China (NMPA) follow the Medical Device Classification Catalog; home devices are mostly Class II (e.g., thermometers) or Class III (e.g., implantable hearing aids).

Step 3: Assess reusability of existing documentation. Existing NMPA registration certificates, CE certificates (MDD/MDR), FDA 510(k) or PMA, ISO 13485, and MDSAP certificates can serve as a technical basis. However, check for country-specific requirements: for example, Japan's PMDA classifies home glucose meters as "Managed Medical Devices (Class II)" requiring JIS standards; Southeast Asian countries have additional testing requirements. A core action is to create a "classification comparison table" listing product codes, risk classes, and registration pathways for all target countries.

Step 4: Confirm requirements for technical documentation, performance validation, risk management, clinical evaluation, or clinical evidence. For reusable documents: ISO 14971 risk management reports (including home-specific hazard analysis) are usually transferable; electrical safety and EMC test reports (IEC 60601 series) must be checked for adopted versions (e.g., IEC 60601-1:2005+A1:2012 vs. 3.2); biocompatibility (ISO 10993) and software lifecycle (IEC 62304) reports are reusable, but home devices need attention to usability engineering (IEC 62366). For clinical evaluation, the EU MDR requires a Clinical Evaluation Report (CER), with some Class IIb devices needing clinical trials; the FDA 510(k) typically only requires clinical data from comparative devices. Among GHWP members, China is promoting a "clinical trial exemption catalog," and most home devices qualify.

Documentation and Evidence

Enterprises must prepare the following to support classification decisions:

• Intended use statement (including target population, environment, contraindications)
• Mechanism of action and technical principle (e.g., electronic sphygmomanometer using oscillometric method)
• Type of body tissue or fluid contacted (skin, blood, airway, etc.)
• Duration of use (single continuous or cumulative)
• Whether the device is used with drugs or substances
• Classification information of similar marketed products (competitors) to support the claimed class
• Existing NMPA registration certificates/test reports, CE/ISO 13485 certificates, FDA 510(k) or premarket notifications, ISO 14971 risk management report summaries, and clinical evaluation reports (e.g., CER) or literature reviews

For multi-country registration in GHWP member states, it is recommended to build a "core technical file package" containing: (1) product description and classification rationale (including GMDN code); (2) intended use and label sample; (3) performance test reports (safety, EMC, usability); (4) risk management report (including home-environment hazard analysis); (5) biocompatibility evaluation; (6) clinical evidence (CER or literature). On this basis, localize for each country: translate labels and instructions, submit local-language risk management summaries, and provide authorized representative/local agent signature documents.

Common Mistakes

• Mistake 1: Directly copying NMPA or FDA classifications without considering specific target-country rules. For example, a home physiotherapy device may be Class II in China but Class IIb under EU MDR Rule 11 due to therapeutic energy output and potential risk.
• Mistake 2: Abusing the "low risk" label for home devices without addressing active device safety requirements. A home UV therapy device, although used for skin conditions, may be carcinogenic and should be at least Class IIb.
• Mistake 3: Ignoring whether the product includes software or mobile apps. If the device works with an app and the app controls core functions, the software may be independently classified (e.g., SaMD). For instance, home blood pressure monitor data management software may be Class II.
• Mistake 4: Skipping usability engineering assessment. Home devices are used by non-professionals; failure to conduct usability tests (or not doing them at all) leads to review deficiencies. The U.S. FDA and EU explicitly require compliance with IEC 62366-1.
• Mistake 5: Choosing the wrong registration pathway. For example, home glucose monitors may be eligible for 510(k), but if using novel algorithms or lacking a substantial equivalent, De Novo or PMA may be required. Companies must assess this early.

Enterprise Preparation Checklist

• List target countries and research their classification rules (download official guidance or consult experts).
• Prepare documents describing intended use, contraindications, use environment, body contact time, etc.
• Draw up a product component list, noting drug-device combinations, animal tissue, or software.
• Collect existing registrations and test reports (NMPA, CE, FDA, other markets).
• Organize ISO 13485/MDSAP certificates and confirm QMS scope.
• For home environment: prepare usability test reports (IEC 62366) and home-specific hazard list in risk management.
• Determine if clinical evaluation or clinical trial is required. Consult the target country authority or notified body early.
• Select and sign a local agent (authorized representative), clarifying scope of responsibilities, including registration, changes, post-market surveillance, and adverse event reporting.
• Develop a post-market surveillance plan (PMS/PMCF), distinguishing annual reporting requirements by risk class.
• Create a multi-country registration timeline and budget, accounting for possible review deficiency costs due to classification differences.

AIMEILI Insights

The most common misjudgment is equating "home use" with "low risk" and skipping necessary clinical evaluation or safety testing. For example, home oxygen concentrators and nebulizers, though not professionally used, involve respiratory function and are managed as Class IIb or Class III in many countries. We recommend conducting a preliminary classification assessment for target countries in the early project phase, using official classification databases (e.g., FDA Product Code, EU MDCG classification guidance, China's Medical Device Classification Catalog) for self-check. If ambiguity exists, schedule pre-submission meetings with notified bodies or local agents (e.g., FDA Pre-Sub, EU Designation).

Among core documents, risk management and usability documents are usually reusable, but clinical evidence and labeling must be localized. Particularly for home products, warnings, icons, and instructions must conform to target country language and cultural norms. The choice of local agent is critical; they are not only responsible for submission but also for post-market surveillance and certificate control. If the certificate is controlled by the agent, switching agents may invalidate the certificate or require re-registration. We recommend specifying certificate ownership in the contract and requiring the agent to return the original registration certificate after approval. For multi-country registration, start with a core technical file and add country-specific differences to avoid repeated resource expenditure and deficiency risks.

Frequently Asked Questions

Q: Are home medical devices always classified lower than professional-use devices?

A: Not necessarily. Classification depends on risk, not use environment. For example, home dialysis machines and home ventilators involve life support and have the same or higher risk class as professional devices. The home environment increases misuse risks, which may require stricter usability testing and warnings.

Q: How is classification considered when a product has both software and hardware?

A: Hardware and software should be assessed separately. Hardware is classified by its own risk. Software, if independently driving (e.g., standalone diagnostic algorithm), follows SaMD rules; if the software is an embedded or auxiliary function, it usually follows the hardware classification. For example, an app paired with a smart blood pressure monitor for data recording and trend display generally has the same class as the monitor (Class II), but if the app provides diagnostic advice, it may be independently classified as Class III.

Q: Can existing CE certificates and FDA 510(k) results be directly used for GHWP member state registration classification?

A: They cannot be directly equated, but they serve as important references. GHWP members mostly adopt GHTF classification rules, which are similar to EU MDR, but local differences exist. For example, home body fat scales are Class I (general medical device) in Japan, while in China they are Class II; Thailand treats them as "non-risk medical devices" but requires listing review. It is recommended to create a classification comparison table and submit inquiries to target country authorities or get quotations.

Source: Compiled from AIMEILI Registration Practice Question Bank, Medical Device International Registration Knowledge Base, and public regulatory information. Specific projects should be based on the latest requirements of target country regulatory authorities and product documentation.